Stock ATRINSIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Atrinsic, Inc. Other OTC

Equities

US04964C2089

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Atrinsic, Inc.
May. 15 Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial
AQ
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
CI
Protagenic Therapeutics, Inc.
AQ
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
AQ
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%
MT
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Reverse Split: 1 of 4
FA
PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director
CI
PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
AQ
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTIX Stock
  4. Stock
  5. News Atrinsic, Inc.